drugset / Trial / NCT01802073
Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
NaSingle-groupOpen-labelTreatment
Summary
Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.
Timeline
- Start
- 2012-01
- Primary completion
- 2015-08
- Completion
- 2015-08
Publications
- Results Abarbanel DN, Seki SM, Davies Y, Marlen N, Benavides JA, Cox K, Nadeau KC, Cox KL. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol. 2013 Feb;33(2):397-406. doi: 10.1007/s10875-012-9801-1. Epub 2012 Oct 9.
- Ali AH, Damman J, Shah SB, Davies Y, Hurwitz M, Stephen M, Lemos LM, Carey EJ, Lindor KD, Buness CW, Alrabadi L, Berquist WE, Cox KL. Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. Scand J Gastroenterol. 2020 Aug;55(8):941-950. doi: 10.1080/00365521.2020.1787501. Epub 2020 Jul 7.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vancomycin | Other / unclassified | 50 mg/kg | Oral |
| Subject | Vancomycin | Other / unclassified | 75 mg/kg | Oral |
| Subject | Vancomycin | Other / unclassified | 100 mg/kg | Oral |
| Subject | Vancomycin | Other / unclassified | 500 mg | Oral |
| Subject | Vancomycin | Other / unclassified | 750 mg | Oral |
| Subject | Vancomycin | Other / unclassified | 1000 mg | Oral |